Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bladder-sparing maintenance sasanlimab trial in molecularly categorized muscle-invasive bladder cancer
2024-511358-36-00Phase 2Authorised
- Sponsor
- Fundación de Investigación HM Hospitales
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sasanlimab in bladder cancer and transitional cell carcinoma (TCC), sponsored by Fundación de Investigación HM Hospitales. Primary endpoint: Bladder-intact overall survival rate at 12 months. Planned start Jul 2024; status: authorised.
02
Drugs
sasanlimab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-511358-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511358-36-00.